Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 259 participants.
Also called NCT03433755
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 259 participants
- Sponsor
- Registry
-
NCT03433755
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China
- Registry status
- Terminated
Technical summary
Registry record NCT03433755. Randomized; quadruple masking; primary purpose treatment. Start 2019-05-09 (actual); primary completion 2020-04-24 (actual). Results posted on 2021-08-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia
- Condition
- Primary Hypercholesterolemia
- Condition
- Mixed Dyslipidemia
- Intervention (Drug)
- evolocumab
- Intervention (Drug)
- placebo
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct03433755- Content hash
d631a1f1d66ea9250627e251079a7ee932342eb612572bf5dcd5af72185dcc88